Effect of Kinesiotaping on Force Irradiation

September 7, 2018 updated by: Bezmialem Vakif University

The Determination of Relationship Between Kinesiotaping and Contralateral Force Irradiation

The study is assessed the electromyographic activity response of non-dominant biceps brachii muscle during unilateral-dominant concentric, eccentric and isometric biceps brachii muscle contractions under kinesiotaping and non-taping conditions. The aim of the study is to determine the synergistic effect of kinesiotaping which is applied on non-dominant biceps brachii muscle on force irradiation.

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Completed

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Detailed Description

Fourty healthy subjects with no history of neurological or recent musculoskeletal injury will participate the study.

Healthy subjects are arranged in two groups of stimulation: kinesiotaping group (kinesiotaping and force irradiation) and control group (only force irradiation). The electromyographic response of the resting arm (non-dominant) will be assessed during the dominant arm movement for all subjects. Additionally, in kinesiotaping group, kinesiotaping will be applied 24 hours before the experiment.

The electromyographic response of the resting arm will be assessed under three contraction type movement (isometric, eccentric and concentric contractions) The SEMG signals are analysed by using MATLAB®, suitable signal proccessing techniques (linear envelope, Root Mean Square etc) are chosed. The statistical analysis are done by using SPSS®, according to data distribution, "Independent Sample T Test" or "Mann-Whitney U Test" is utilized for comparing outcomes of control and KT groups.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Interventional

Enrollment (Actual)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
40

Phase

Phase

The stage of a clinical trial studying a drug or biological product, based on definitions developed by the U.S. Food and Drug Administration (FDA). The phase is based on the study's objective, the number of participants, and other characteristics. There are five phases: Early Phase 1 (formerly listed as Phase 0), Phase 1, Phase 2, Phase 3, and Phase 4. Not Applicable is used to describe trials without FDA-defined phases, including trials of devices or behavioral interventions.
  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Turkey
      • Istanbul, Turkey
        • Bezmialem Vakıf University

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

18 years to 30 years (Adult)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • To be right-handed-dominant
  • To have normal or corrected vision
  • To have no formal history of any resistance training.

Exclusion Criteria:

  • To have history of neurological or recent musculoskeletal injury

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm

Participant Group / Arm

A group or subgroup of participants in a clinical trial that receives a specific intervention/treatment, or no intervention, according to the trial's protocol.
Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.
Experimental: Kinesiotaping Group
The group in which kinesiotaping is applied to non-dominant biceps brachii muscle of participants before 24 hours the force irradiation experiment.
Other: Force Irradiation
For the force irradiation, while the subjects perform dominant elbow flexion at an angular velocity of 60°/s for concentric contractions, 30°/s for eccentric contractions, at 90° elbow flexion position for isometric contractions with a maximal effort level, electrical activity of the non-dominant biceps brachii and triceps brachii muscles are recorded.
Other: Kinesiotaping
For kinesiotaping, the elbow positioned in 30°-45° flexion and kinesiotaping facilitation technique is applied origin to insertion of non-dominant biceps brachii muscle before 24 hours the experiment.
Other Names:
  • Force Irradiation
Active Comparator: Control group
The group in which the participants only perform the the force irradiation experiment.
Other: Force Irradiation
For the force irradiation, while the subjects perform dominant elbow flexion at an angular velocity of 60°/s for concentric contractions, 30°/s for eccentric contractions, at 90° elbow flexion position for isometric contractions with a maximal effort level, electrical activity of the non-dominant biceps brachii and triceps brachii muscles are recorded.

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Measure Description
Time Frame
Measurement of the surface electromyographic activity of left biceps brachii muscle by using surface electromyography device while the right elbow performs isometric elbow flexion
Time Frame: after inclusion
while the right elbow performs isometric elbow flexion, electromyographic activity of left biceps brachii was determined by using surface electromyography device. After signal processing and normalization, the electromyographic data of kinesiotaping and control groups will be compared.
after inclusion
Measurement of the surface electromyographic activity of left triceps brachii muscle by using surface electromyography device while the right elbow performs isometric elbow flexion
Time Frame: after inclusion
while the right elbow performs isometric elbow flexion, electromyographic activity of left triceps brachii was determined by using surface electromyography device. After signal processing and normalization, the electromyographic data of kinesiotaping and control groups will be compared.
after inclusion
Measurement of the surface electromyographic activity of left biceps brachii muscle by using surface electromyography device while the right elbow performs concentric elbow flexion.
Time Frame: after inclusion
while the right elbow performs concentric elbow flexion, electromyographic activity of left biceps brachii was determined by using surface electromyography device. After signal processing and normalization, the electromyographic data of kinesiotaping and control groups will be compared.
after inclusion
Measurement of the surface electromyographic activity of left triceps brachii muscle by using surface electromyography device while the right elbow performs concentric elbow flexion
Time Frame: after inclusion
while the right elbow performs isometric elbow flexion, electromyographic activity of left triceps brachii was determined by using surface electromyography device. After signal processing and normalization, the electromyographic data of kinesiotaping and control groups will be compared.
after inclusion
Measurement of the surface electromyographic activity of left biceps brachii muscle by using surface electromyography device while the right elbow performs eccentric elbow flexion
Time Frame: after inclusion
while the right elbow performs eccentric elbow flexion, electromyographic activity of left biceps brachii was determined by using surface electromyography device. After signal processing and normalization, the electromyographic data of kinesiotaping and control groups will be compared.
after inclusion
Measurement of the surface electromyographic activity of left triceps brachii muscle by using surface electromyography device while the right elbow performs eccentric elbow flexion
Time Frame: after inclusion
while the right elbow performs eccentric elbow flexion, electromyographic activity of left triceps brachii was determined by using surface electromyography device. After signal processing and normalization, the electromyographic data of kinesiotaping and control groups will be compared.
after inclusion

Secondary Outcome Measures

Secondary Outcome Measures

In a clinical study's protocol, a planned outcome measure that is not as important as the primary outcome measure for evaluating the effect of an intervention but is still of interest. Most clinical studies have more than one secondary outcome measure.
Outcome Measure
Measure Description
Time Frame
Measurement of the electromyographic activity of left biceps brachii muscle during left elbow maximum isometric flexion by using electromyography device.
Time Frame: after inclusion
Electromyographic activity of left elbow maximum isometric flexion is used for normalizing force irradiation data of left biceps brachii muscle
after inclusion
Measurement of the electromyographic activity of left triceps brachii muscle during left elbow maximum isometric extension by using electromyography device.
Time Frame: after inclusion
Electromyographic activity of left elbow maximum isometric extension is used for normalizing force irradiation data of left triceps brachii muscle
after inclusion

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
Bezmialem Vakif University

Collaborators

Collaborators

An organization other than the sponsor that provides support for a clinical study. This support may include activities related to funding, design, implementation, data analysis, or reporting.
Istanbul University

Investigators

Investigators

A researcher involved in a clinical study. Related terms include site principal investigator, site sub-investigator, study chair, study director, and study principal investigator.
  • Study Director: Aydın AKAN, Istanbul University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
August 10, 2017

Primary Completion (Actual)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
May 20, 2018

Study Completion (Actual)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
September 3, 2018

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
February 6, 2018

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
March 19, 2018

First Posted (Actual)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
March 20, 2018

Study Record Updates

Last Update Posted (Actual)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
September 10, 2018

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
September 7, 2018

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
September 1, 2018

More Information

Terms related to this study

Keywords

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • hdenizkulli

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Healthy

Clinical Trials on Force Irradiation

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings